Table 1.
Baseline characteristics of the patients subjected to efficacy analysis
| Menatetrenone | Alfacalcidol | P-value | |
|---|---|---|---|
| Number of patients | 108 | 105 | |
| Age, years | 64.6±6.1 | 64.2±6.3 | 0.649 |
| Years since menopause | |||
| Age, years | 15.1±6.5 | 15.6±6.6 | 0.591 |
| Height, cm | 154.2±5.4 | 155.0±5.0 | 0.267 |
| Weight, kg | 55.2±7.2 | 56.2±7.3 | 0.322 |
| Previous vertebral fracture, number (%) | 14 (13.0) | 12 (11.4) | 0.732 |
| Bone mineral density, mg/cm2 | |||
| Lumbar spine | 805.0±115.1 | 793.7±99.9 | 0.654 |
| Femoral neck | 644.6±101.1 | 654.1±97.8 | 0.374 |
| Trochanter | 561.0±94.1 | 567.8±81.5 | 0.644 |
| Serum calcium, mmol/L | 2.37±0.09 | 2.37±0.11 | 0.796 |
| Serum phosphate, mmol/L | 1.25±0.15 | 1.23±0.18 | 0.434 |
| Serum total ALP, U/L | 75.5±19.4 | 73.7±18.9 | 0.479 |
| Serum OC, ng/mL | 27.8±8.5 | 26.1±8.5 | 0.088 |
| Serum ucOC, ng/mL | 2.7±2.2 | 2.4±1.9 | 0.305 |
| Serum ucOC/OC | 0.09±0.06 | 0.09±0.07 | 0.509 |
Abbreviations: ALP, alkaline phosphatase; OC, osteocalcin; ucOC, undercarboxylated osteocalcin.